RFM
VKTX icon

Royal Fund Management’s Viking Therapeutics VKTX Stock Holding History

Royal Fund Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$817K Sell
20,943
-33
-0.2% -$1.07K 0.07% 201
2026
Q1 		$683K Sell
20,976
-22,176
-51% -$713K 0.06% 199
2025
Q4 		$1.52M Buy
+43,152
New +$1.53M 0.14% 156
2025
Q3 		– Sell
-21,376
Closed -$566K – 352
2025
Q2 		$566K Buy
21,376
+485
+2% +$12.8K 0.06% 226
2025
Q1 		$505K Sell
20,891
-23,291
-53% -$736K 0.06% 234
2024
Q4 		$1.78M Buy
44,182
+32,438
+276% +$1.85M 0.17% 138
2024
Q3 		$744K Buy
11,744
+344
+3% +$20.2K 0.04% 233
2024
Q2 		$604K Buy
+11,400
New +$747K 0.05% 226

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Royal Fund Management's VKTX Position: Q2 2026 in Review

Royal Fund Management reduced its Viking Therapeutics (VKTX) stake by 0.16% in Q2 2026, selling an estimated $1.07K and leaving 20,943 shares worth $817K. The position accounts for 0.07% of the portfolio, ranked #201.

Royal Fund Management first reported a position in VKTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.78M in Q4 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Royal Fund Management held 20,943 shares of Viking Therapeutics worth $817K as of Q2 2026.
  • Royal Fund Management sold 33 Viking Therapeutics shares in Q2 2026, an estimated $1.07K.
  • Viking Therapeutics made up 0.07% of Royal Fund Management's portfolio in Q2 2026, its #201 holding.
  • Royal Fund Management first reported a position in Viking Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Royal Fund Management's Viking Therapeutics position peaked at $1.78M in Q4 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Royal Fund Management's 13F filing for Q2 2026, filed 20 Jul 2026.